CRVS Overview

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Wall Street analysts forecast CRVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVS is13.33 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Corvus Pharmaceuticals Inc revenue for the last quarter amounts to -12.22M USD, increased 50.73

Corvus Pharmaceuticals Inc. EPS for the last quarter amounts to -9216000.00 USD, increased 8.87

Corvus Pharmaceuticals Inc (CRVS) has 29 emplpoyees as of April 19 2026.

Today CRVS has the market capitalization of 1.41B USD.